RxDoctor Payments Data

Hooman Melamed

Marina del Rey, CANPI 1447350053

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $177,167 of the $200,415 with a category attached, or 88.4%. Aegis Spine, Inc. accounts for 89.1% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2020 at $181,544 and has fallen 96.8% since, to $5,848 in 2025.

$200,415in general payments, 2019–2025

Across 55 payments — averaging $3643.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aegis Spine, Inc.$179K
  • Kyocera Medical Technologies, Inc.$8K
  • Solco Biomedical Corporation$6K
  • Medtronic$4K
  • Seaspine Orthopedics Corporation$2K
  • Centinel Spine, LLC$829
  • plus $666 from 8 others

What the payments were for

  • Royalty or licence$177,16788%
  • Consulting fees$16,8298%
  • Travel & lodging$5,4323%
  • Food & beverage$9870%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib41$1,225
Pregabalin45$347
Tramadol Hcl32$255

Paid to pharmacies, not to this prescriber.

Where these figures come from

Is this you, or does something look wrong? →